[go: up one dir, main page]

PE20091093A1 - Compuesto heterociclico que contiene nitrogeno y su uso - Google Patents

Compuesto heterociclico que contiene nitrogeno y su uso

Info

Publication number
PE20091093A1
PE20091093A1 PE2008002010A PE2008002010A PE20091093A1 PE 20091093 A1 PE20091093 A1 PE 20091093A1 PE 2008002010 A PE2008002010 A PE 2008002010A PE 2008002010 A PE2008002010 A PE 2008002010A PE 20091093 A1 PE20091093 A1 PE 20091093A1
Authority
PE
Peru
Prior art keywords
piperidin
substituted
dichlorophenyl
carbonyl
methylbenzamide
Prior art date
Application number
PE2008002010A
Other languages
English (en)
Inventor
Yoshinori Ikeura
Junya Shirai
Hideyuki Sugiyama
Yuji Nishikimi
Taku Kamei
Nobuki Sakauchi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20091093A1 publication Critical patent/PE20091093A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES HETEROCICLOQUE CONTIENE N SUSTITUIDO O NO; B ES ANILLO AROMATICO SUSTITUIDO O NO; C ES UN GRUPO CICLICO SUSTITUIDO O NO; R1 ES H, ACILO, HETEROCICLO SUSTITUIDO O NO, ENTRE OTROS; R2 ES ALQUILO C1-C6 SUSTITUIDO O NO POR HALOGENO; m Y n SON CADA UNO 0-5 DONDE m+n ES UN NUMERO ENTERO DE 2-5; --- ES UN ENLACE SIMPLE O DOBLE. SON COMPUESTOS PREFERIDOS: N-[(3R,4R)-1-[(1-ACETILPIPERIDIN-4-IL)CARBONIL]-3-(3,4-DICLOROFENIL)PIPERIDIN-4-IL]-N-METIL-3,5-BIS(TRIFLUOROMETIL)BENZAMIDA; 4-CLORO-N-[(3R,4R)-3-(3,4-DICLOROFENIL)-1-{[1-(HIDROXIACETIL)PIPERIDIN-4-IL]CARBONIL}PIPERIDIN-4-IL]-N-METILBENZAMIDA; 4-BROMO-N-[(3R,4R)-3-(3,4-DICLOROFENIL)-1-{[1-(HIDROXIACETIL)PIPERIDIN-4-IL]CARBONIL}PIPERIDIN-4-IL]-N-METILBENZAMIDA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE TAQUININA UTILES EN EL TRATAMIENTO DE VESIVULA SUPER ACTIVA, SINDROME DEL INSTESTINO IRRITABLE, DISPEPSIA FUNCIONAL, ENFERMEDAD INFLAMATORIA INTESTINAL, ENTRE OTROS
PE2008002010A 2007-12-03 2008-12-02 Compuesto heterociclico que contiene nitrogeno y su uso PE20091093A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99673407P 2007-12-03 2007-12-03

Publications (1)

Publication Number Publication Date
PE20091093A1 true PE20091093A1 (es) 2009-08-25

Family

ID=40340719

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002010A PE20091093A1 (es) 2007-12-03 2008-12-02 Compuesto heterociclico que contiene nitrogeno y su uso

Country Status (6)

Country Link
US (1) US8470816B2 (es)
AR (1) AR069526A1 (es)
CL (1) CL2008003595A1 (es)
PE (1) PE20091093A1 (es)
TW (1) TW200930713A (es)
WO (1) WO2009072643A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2297098A1 (en) * 2008-06-16 2011-03-23 F. Hoffmann-La Roche AG Pyrrolidine derivatives as nk2 receptor antagonists
USRE49686E1 (en) 2008-09-19 2023-10-10 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8022099B2 (en) * 2008-11-03 2011-09-20 Hoffmann-La Roche Inc. N-benzyl pyrrolidine derivatives
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
EP2361912A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
SI2552920T1 (sl) 2010-04-02 2017-07-31 Ogeda Sa Nove nk-3 receptor selektivne antagonist spojine, farmacevtski sestavki in postopki za uporabo pri nk-3 receptor posredovanih motnjah
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
US9428547B2 (en) 2010-04-21 2016-08-30 Dna Electronics, Inc. Compositions for isolating a target analyte from a heterogeneous sample
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
WO2013050424A1 (en) * 2011-10-03 2013-04-11 Euroscreen S.A. NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
US9359330B2 (en) * 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
WO2015161011A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Benzamide cgrp receptor antagonists
ES2838573T3 (es) * 2014-08-21 2021-07-02 Bristol Myers Squibb Co Derivados de benzamida ligados como inhibidores potentes de ROCK
BR112017004589A2 (pt) * 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
JP6706250B2 (ja) * 2015-04-20 2020-06-03 武田薬品工業株式会社 複素環化合物
AU2017208970A1 (en) * 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
EP3530655B1 (en) 2016-10-18 2022-02-09 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2018152286A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
KR20190129867A (ko) * 2017-02-17 2019-11-20 트레베나, 인코포레이티드. 5-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
US20220016115A1 (en) 2018-12-06 2022-01-20 Almac Discovery Limited Usp19 inhibitors for use in therapy
CN110357882B (zh) * 2019-07-17 2020-10-16 深圳市华星光电半导体显示技术有限公司 含氮杂环的有机化合物及有机电致发光器件
CN111961020A (zh) * 2020-08-31 2020-11-20 南通大学 一种四氢吡喃羧酸衍生物及其合成方法
EP4011877A3 (en) * 2020-12-11 2023-01-11 Institut de Cardiologie de Montréal Method of treating elevated plasma cholesterol
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
GB202311227D0 (en) 2023-07-21 2023-09-06 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288725A (en) * 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
IT1283171B1 (it) 1996-03-01 1998-04-16 Interdipartimentale Di Ricerca Composti solubili antagonisti delle tachichinine loro preparazione e loro uso in composizioni farmaceutiche
JP2004517062A (ja) 2000-11-13 2004-06-10 グラクソスミスクライン・ソシエタ・ペル・アチオニ Ｎｋ−３およびｎｋ−２アンタゴニストとしてのキノリン誘導体
GB0027701D0 (en) 2000-11-13 2000-12-27 Smithkline Beecham Spa Novel compounds
EP1385839B1 (en) 2001-04-11 2006-02-22 GlaxoSmithKline S.p.A. 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
AU2003241903A1 (en) * 2002-05-31 2003-12-19 Takeda Pharmaceutical Company Limited Piperidine derivative, process for producing the same, and use
AU2003902882A0 (en) * 2003-06-10 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Piperidyl derivatives
WO2005068427A1 (ja) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited カルボキサミド誘導体およびその用途
BRPI0510365A (pt) 2004-04-28 2007-11-06 Takeda Pharmaceutical composto, método de produção de um composto, antagonista do receptor nk2, pró-droga, agente farmacêutico, métodos para antagonizar um recpetor nk2 e para evitar ou tratar doenças gastrintestinais funcionais, e, uso do composto ou uma pró-droga do mesmo
BRPI0510951A (pt) * 2004-05-12 2007-11-20 Pfizer Prod Inc derivados de piperidina como antagonistas de nk1 e nk3
SE0403005D0 (sv) 2004-12-09 2004-12-09 Astrazeneca Ab New use
JPWO2008093737A1 (ja) * 2007-01-31 2010-05-20 大日本住友製薬株式会社 アミド誘導体
JP2010163361A (ja) * 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd キノリン誘導体

Also Published As

Publication number Publication date
WO2009072643A1 (en) 2009-06-11
US8470816B2 (en) 2013-06-25
US20090156572A1 (en) 2009-06-18
AR069526A1 (es) 2010-01-27
CL2008003595A1 (es) 2009-11-20
TW200930713A (en) 2009-07-16

Similar Documents

Publication Publication Date Title
PE20091093A1 (es) Compuesto heterociclico que contiene nitrogeno y su uso
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20040951A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
AR006545A1 (es) Compuestos sustitutos de las catecolaminas, utiles como antagonistas beta3, composiciones farmaceuticas que los contienen y compuestos intermediarios deaplicacion exclusiva en la preparacion de dichos compuestos
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
NO20076478L (no) Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
DK2029529T3 (da) Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
PE20061088A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
PE20140968A1 (es) Derivados de benzamida sustituida
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
UY29421A1 (es) Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones.
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
PE20060627A1 (es) Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
NO20071314L (no) Peptidiske vasopressinreseptoragonister
ATE537170T1 (de) Cgrp-rezeptorantagonisten
DK1778677T3 (da) Heterocykliske kondenserede forbindelser der er egnede som antidiuretiske midler
EA200601895A1 (ru) 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
NO20080750L (no) (Indol-3-YL)-heterocykelderivater som agonister av cannabinoid CB1 reseptor

Legal Events

Date Code Title Description
FD Application declared void or lapsed